Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
46 hedge funds and large institutions have $70.2M invested in Talis Biomedical Corporation Common Stock in 2021 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 16 reducing their positions, and 5 closing their positions.
160% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 5
21% more funds holding
Funds holding: 38 → 46 (+8)
14% more call options, than puts
Call options by funds: $84K | Put options by funds: $74K
31% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 16
41% less capital invested
Capital invested by funds: $119M → $70.2M (-$49M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Greenlight Capital
New York
|
+$7.83M |
| 2 |
PCM
Prelude Capital Management
New York
|
+$877K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$780K |
| 4 |
Two Sigma Investments
New York
|
+$392K |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$249K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$9.69M |
| 2 |
NIP
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$6.18M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.88M |
| 4 |
Morgan Stanley
New York
|
-$690K |
| 5 |
Bank of New York Mellon
New York
|
-$166K |
TLIS Hedge Fund Activity: Q4 2021 in Review
46 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q4 2021, worth a combined $70.2M — down 41% from $119M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new TLIS positions and 5 closed out — a net gain of 8 holders — while 11 added to existing stakes and 16 trimmed.
The largest buyer was Greenlight Capital, opening a new position worth an estimated $7.83M. The largest seller was Boxer Capital, exiting entirely with an estimated $9.69M sold.
- 46 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q4 2021, up from 38 in Q3 2021.
- Funds reported $70.2M of Talis Biomedical Corporation Common Stock stock for Q4 2021, down 41% quarter-over-quarter.
- 13 funds opened new Talis Biomedical Corporation Common Stock positions in Q4 2021 and 5 closed out, a net change of +8 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q4 2021 was Greenlight Capital, an estimated $7.83M added.
- The largest Talis Biomedical Corporation Common Stock seller in Q4 2021 was Boxer Capital, an estimated $9.69M sold.
Based on aggregated 13F filings for Q4 2021.